NEW DELHI –In the wake of the death of a U.S. woman who had been infected with a drug-resistant bug in India, the country's drug regulator has ordered all companies involved in the drug supply chain system to strictly follow the country's guidelines in the Drugs and Cosmetics Act on the sale of medicines.
NEW DELHI – Indian pharmaceutical companies will continue to grow through acquisitions of overseas assets in the next 18 to 24 months, with the aim of deepening their geographic and product diversity and increasing their presence in developed and emerging markets, according to a recent report by Moody's Analytics.
NEW DELHI – Indian pharmaceutical companies will continue to grow through acquisitions of overseas assets in the next 18 to 24 months, with the aim of deepening their geographic and product diversity and increasing their presence in developed and emerging markets, according to a recent report by Moody's Analytics.
NEW DELHI – Looking to keep up with global trends, Indian pharma has moved to speed up its push toward more digitization, but it has a long way to go before it catches up with advanced countries, pharma industry analysts say.
NEW DELHI – Looking to keep up with global trends, Indian pharma has moved to speed up its push toward more digitization, but it has a long way to go before it catches up with advanced countries, pharma industry analysts say.
NEW DELHI – The Delhi High Court has set aside the Indian government's notification to ban 344 fixed-dose combination (FDC) medicines, which include some well-known branded cough syrups, saying the Indian government acted in a "haphazard manner."
NEW DELHI – The Delhi High Court has set aside the Indian government's notification to ban 344 fixed-dose combination (FDC) medicines, which include some well-known branded cough syrups, saying the Indian government acted in a "haphazard manner."
NEW DELHI – Marking what may be a first, Mylan NV and Biocon Ltd. have submitted Mylan's biologics license application (BLA) to the FDA for a proposed biosimilar of branded trastuzumab, MYL-1401O, to treat certain forms of breast and gastric cancers.
NEW DELHI – Marking what may be a first, Mylan NV and Biocon Ltd. have submitted Mylan's biologics license application (BLA) to the FDA for a proposed biosimilar of branded trastuzumab, MYL-1401O, to treat certain forms of breast and gastric cancers.
